#Position AA Comment NotAA 90 I The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 98 G The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 100 I The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 101 E The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 101 P The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 106 I The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 179 D The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 179 F The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 181 C The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 181 I The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 181 V The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 190 A The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 190 S The following $numberOfMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} of the 13 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EP,106I,179DF,181CIV,190AS} (Katlama C et al, IAS 2007). 74 VI $listHitsAt{74} partially reverses AZT and possibly d4T resistance caused by other mutations. AZT mutations in this isolate include: $listHitsAt{41,67,70,210,215,219}. L 100 I $listHitsAt{100} partially reverses AZT and possibly d4T resistance caused by other mutations. AZT mutations in this isolate include: $listHitsAt{41,67,70,210,215,219}. L 181 Y $listHitsAt{181} partially reverses AZT and possibly d4T resistance caused by other mutations. AZT mutations in this isolate include: $listHitsAt{41,67,70,210,215,219}. I 184 VI $listHitsAt{184} partially reverses AZT, d4T, and TDF resistance caused by other AZT mutations (TAMs). AZT mutations in this isolate include: $listHitsAt{41,67,70,210,215,219}. M 41 L M41L usually occurs with T215Y. Together these mutations confer intermediate-to-high level resistance to AZT and d4T and a lower level of resistance to ddI, ABC, and TDF. 44 DA E44A/D occur in patients receiving multiple NRTIs. E44D causes low-level resistance to 3TC and probably to each of the other NRTIs when present with V118I or one or more TAMs. 62 V A62V is associated with multinucleoside resistance caused by Q151M; its effect in the absence of Q151M is not known. 65 R K65R causes intermediate resistance to ddI, ABC, 3TC, FTC, and TDF, and low-level resistance to d4T. K65R causes AZT hypersusceptibility. 65 N K65N is a rare mutation that is associated with reduced susceptibility to ddI, ABC, 3TC, FTC and TDF. 67 N D67N contributes some degree of resistance to each of the NRTIs except 3TC and FTC. It usually occurs with mutations at positions 70 or 215. 67 EG D67N contributes some degree of resistance to each of the NRTIs except 3TC and FTC. It usually occurs with mutations at positions 70 or 215. D67E/G occur in heavily treated patients but their precise effect on NRTI susceptibility is not known. 67 d Amino acid deletions (d) in this region occur uncommonly and are often assigned to position 67. They occur in combination with other NRTI mutations and contribute decreased susceptibility to each of the NRTIs. 69 D T69D contributes resistance to ddI and d4T. 69 NSAI T69N/S/A/I are NRTI-selected mutations but their effect on NRTI susceptibility is not known. 69 G T69G occurs in isolates with a deletion at position 67 but its effect on NRTI susceptibility is not known. 69 i Amino acid insertions (i) at this position occur in about 1%-2% of heavily treated persons. Together with TAMs, they confer high-level resistance to each of the NRTIs. Most susceptibility data are available for double amino acid insertions. However, insertions of 1 or >2 amino acids also occur. 70 R K70R causes low-level AZT, d4T, and possibly TDF resistance and appears to have little if any effect on the other NRTIs. 70 E K70E reduces TDF, ABC, DDI, and to a lesser extent 3TC and FTC susceptibility. K70E does not reduce AZT or d4T susceptibility. 70 N K70N is a rare NRTI-selected variant. Its effect on drug susceptibility is not known. 70 G K70G appears to reduce TDF, ABC, DDI, and to a lesser extent 3TC and FTC susceptibility. K70G does not reduce AZT susceptibility. Its effect on d4T susceptibility is not known. 74 V L74V reduces ddI and ABC susceptibility. L74V increases AZT and TDF susceptibility. 74 I L74I, like L74V, reduces ddI and ABC susceptibility. 75 I V75I increases multinucleoside resistance caused by Q151M when present with F77L and F116Y; its effect in the absence of Q151M is not known. 75 T V75T reduces d4T and ddI susceptibility. 75 S Like V75T, V75S may also reduce d4T and ddI susceptibility. 75 MA V75TM/A reduce d4T and possibly ddI susceptibility. 77 L F77L increases multinucleoside resistance caused by Q151M when present with V75I or F116Y; its effect in the absence of Q151M is not known. 115 F Y115F causes intermediate resistance to ABC and low-level resistance to TDF. 116 Y F116Y increases multinucleoside resistance caused by Q151M when present with F77L or V75I; its effect in the absence of Q151M is not known. 118 I V118I occurs in ~2% of untreated persons and with increased frequency in persons receiving multiple NRTIs. It causes low-level resistance to 3TC and possibly to other NRTIs when present with E44A/D and/or one or more TAMs. 151 M By itself, Q151M causes intermediate resistance to AZT, ddI, d4T, and ABC; and low-level resistance to TDF. With changes at the associated positions 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T, and ABC; intermediate resistance to TDF, and low-level resistance to 3TC and FTC. 151 L By itself, Q151M causes intermediate resistance to AZT, ddI, d4T, and ABC; and low-level resistance to TDF. With changes at the associated positions 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T, and ABC; intermediate resistance to TDF, and low-level resistance to 3TC and FTC. Q151L is a rarely observed transitional mutation that appears to precede the emergence of the Q151M. 184 VI M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level in vitro resistance to ddI and ABC. M184V/I increase susceptibility to AZT, TDF, and d4T. 210 W L210W contributes resistance to each of the NRTIs except 3TC and FTC. It usually occurs with the mutations M41L and T215Y. 210 FS L210W contributes resistance to each of the NRTIs except 3TC and FTC. It usually occurs with the mutations M41L and T215Y. L210F/S occur rarely and are of unknown significance. 215 Y T215Y causes AZT and D4T resistance and reduces susceptibility to ABC, ddI, and TDF particularly when it occurs in combination with M41L and L210W. 215 F T215F causes AZT and D4T resistance and reduces susceptibility to ABC, ddI, and to a lesser extent TDF. 215 SCDEIVAN T215S/C/D/E/I/V/A/N represent transitions between wild type and the mutations Y and F. Most of these mutations do not reduce NRTI susceptibility but their presence suggests that a resistant virus may have been transmitted. 219 QE K219Q/E decrease AZT and probably d4T susceptibility when present with K70R or T215Y/F but have little if any effect on the remaining NRTIs. 219 NR K219N/R occur commonly in heavily NRTI-treated patients. Their effect on NRTI susceptibility is uncertain. 333 DE G333D/E are polymorphisms that occur more frequently in persons receiving NRTIs than in untreated persons. They may facilitate AZT resistance in isolates that contain M184V and multiple TAMs. 98 G A98G occurs in about 1% of NNRTI-naive persons and causes low-level NVP resistance. 98 S A98G occurs in about 1% of NNRTI-naive persons and causes low-level NVP resistance. A98S is a common polymorphism that does not reduce NNRTI susceptibility. 100 I L100I causes intermediate resistance to NVP, DLV, and EFV, and low-resistance to ETR. It nearly always in combination with K103N. L100I increases susceptibility to AZT and TDF. 101 E K101E is associated with intermediate resistance to NVP and DLV and low-level resistance to EFV and ETR. 101 P K101P usually occurs with K103N and in this setting causes high-level resistance to NVP, DLV, and EFV and low-intermediate resistance to ETR. 101 QR K101Q/R occasionally occur in untreated persons and do not decrease NNRTI susceptibility. 101 HN K101H/N are NNRTI-associated mutations with uncertain phenotypic and clinical effects. 103 N K103N causes high-level resistance to NVP, DLV, and EFV. By itself it has no effect on ETR susceptibility. 103 S K103S causes high-level resistance to NVP and intermediate resistance to DLV and EFV. 103 TH K103T/H are rare mutations that appear to be associated with high-level resistance to NVP, DLV, and EFV. 103 R K103R occurs in about 1%-2% of untreated persons and by itself has no effect on NNRTI susceptibility. However, the combination of K103R + V179D, reduces intermediate resistance to NVP, DLV, and EFV. 103 Q K103Q is a rare mutation. It has not been associated with NNRTI resistance. 106 A V106A causes high-level NVP resistance, intermediate DLV resistance, and low-level EFV and ETR resistance. 106 M V106M causes high-level resistance to NVP, EFV, and DLV but does not appear to decrease ETR susceptibility. 106 I V106I is a common polymorphism that does not decrease NNRTI susceptibility. However, in a multivariate analysis it was associated with decreased ETR response in the DUET study. 106 L V106L is a rare mutation of uncertain significance. 108 I V108I causes low-level reductions in susceptibility to each of the NNRTIs except possibly ETR. 138 K E138K is selected in vitro by ETR and reduces its susceptibility by about 5-fold. E138K reduces susceptibility other NNRTIs by about 2-5 fold. 179 DE V179D/E cause low-level reductions in susceptibility to each of the NNRTIs. V179D occurs in about 1% of untreated persons. The combination of K103R + V179D reduces the susceptibility of NVP, DLV, and EFV by about 15-fold; the combination's effect on ETR is not known. 179 F V179F nearly always occurs in combination with Y181C. The combination of V179F + Y181C reduces ETR susceptibility >100-fold and causes low-level EFV resistance. 179 I V179I is a common polymorphism that does not decrease NNRTI susceptibility. 181 CIV Y181C/I/V cause high-level resistance to NVP and DLV and low-level resistance to EFV. Y181C/I/V reduces ETR susceptibility by 5-10 fold and lays the mutational foundation for the development of higher levels of ETR resistance. Y181C increases susceptibility to AZT and TDF. 188 L Y188L causes high-level resistance to NVP and EFV and low-level resistance to ETR and DLV. 188 H Y188H causes low-level resistance to NVP, EFV, and DLV and has been selected in vitro by ETR. 188 C Y188C causes high-level resistance to NVP and low-level resistance to EFV and DLV; its effect on ETR is not known. 190 A G190A causes high level resistance to NVP, intermediate resistance to EFV, and low-level ETR resistance. G190A increases DLV susceptibility. 190 S G190S causes high-level resistance to NVP and EFV and low-level / intermediate resistance to ETR. G190S increases DLV susceptibility. 190 EQ G190E/Q cause high-level resistance to NVP and EFV and intermediate resistance to DLV. G190E + Y181C is associated with >100-fold decreased ETR susceptibility. 190 CTV G190C/T/V are rare mutations that cause high-level resistance to NVP and EFV and variable resistance to DLV. Their effect on ETR is not known. 225 H P225H increases EFV resistance when present in combination with K103N. 227 L F227L usually occurs in combination with V106A and in this setting is associated with high level resistance to NVP and intermediate resistance to DLV and EFV. Its effect on ETR is not known. 227 C F227C is a rare mutation which has been associated with inconsistently reported levels of resistance to each of the NNRTIs particularly ETR. 230 L M230L causes intermediate-to-high-level resistance to each of the NNRTIs. It has been selected in vitro by ETR and reduces ETR susceptibility by about 10-fold. 234 I 234I has been selected in vitro by etravirine and it acts synergistically with Y181C to reduce etravirine susceptibility. Its clinical significance and effect on other NNRTIs is not known. 236 L P236L causes high-level DLV resistance. 238 NT K238N/T are NNRTI-selected mutations that usually occur in combination with other NNRTI-resistance mutations and which appear to confer intermediate levels of resistance to NVP and possibly DLV and EFV. 238 R K238R is a naturally occurring variant that is common in some non-B subtypes and does not reduce NNRTI susceptibility. 318 F Y318F is a rare mutation that causes high-level DLV resistance and low/intermediate NVP resistance. It usually occurs with other NNRTI-associated mutations.